Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 9th Preview)
-
CRISPR edits mitochondria: fresh path for heart-failure repair
Researchers reported a CRISPR-based method that reprograms mitochondrial function after myocardial injury, proposing a direct genetic route to restore cardiac energy metabolism. The study details how targeted edits improved mitochondrial performance in models of post-infarct heart failure, addressing a major contributor to progressive cardiac decline. In a second cardiac study, scientists showed that restoring RBM22 — an RNA-binding protein — reactivated cardiomyocyte proliferation signals previously thought shut in adult hearts. The RBM22 work demonstrated molecular and transcriptional shifts consistent with renewed regenerative capacity in preclinical models. Together these reports point to two distinct intervention strategies: correcting organelle-level bioenergetics via genome editing and resetting nuclear RNA programs to permit cardiomyocyte cell-cycle entry. Both efforts are early-stage but highlight multiple molecular entry points for therapeutic development against chronic heart failure.
-
Listeria repurposed: bacteria deliver cancer payloads to colorectal tumors
Baylor University researchers engineered Listeria monocytogenes to act as a vector that invades colorectal tumors and delivers cytotoxic proteins directly into cancer cells. The study shows the modified bacterium can transport therapeutic payloads into tumor tissue, enabling localized protein-based killing of malignant cells in preclinical models. The approach leverages Listeria’s innate invasive biology to bypass some barriers of systemic delivery; investigators emphasize engineered safety controls and payload specificity. The team frames the platform as a potential complement to existing immunotherapies and targeted agents, pending further safety and dosing work.
-
Bristol Myers’ CELMoD wins...mezigdomide shows PFS gain
Bristol Myers Squibb announced that mezigdomide, an oral protein-degrading CELMoD, met a primary endpoint in a late-stage trial for relapsed or refractory multiple myeloma, showing a statistically significant improvement in progression-free survival versus standard-of-care backbones. The company said safety observations were consistent with known profiles and that detailed results will be presented at a future medical meeting. BMS framed the readout as an incremental de-risking of its broader CELMoD program, a strategic priority as key patents on legacy sellers near expiry. Management and analysts emphasized the readout alongside earlier iberdomide data as evidence the targeted protein-degradation platform could supply next-generation multiple myeloma therapies.
-
Xenon’s azetukalner halves focal seizures – paves way for FDA filing
Xenon Pharmaceuticals reported a positive Phase 3 X-Tole2 study for azetukalner, a KV7 potassium channel opener, with large placebo-adjusted reductions in focal-onset seizure frequency and a tolerable safety profile. The company said the result exceeded expectations and plans to file for FDA approval in the third quarter. Investors reacted strongly to the readout and analysts noted the drug’s oral, once-daily profile and combination potential. Xenon highlighted dose-dependent adverse events but positioned the lower dose as commercially attractive given efficacy and tolerability trade-offs.
-
Ipsen withdraws Tazverik: safety monitors flag secondary blood cancers
Ipsen announced a voluntary withdrawal of tazemetostat (Tazverik) after an independent data monitoring committee identified cases of secondary hematologic malignancies in a confirmatory trial in follicular lymphoma. The company said it is discontinuing clinical studies of the drug and will stop market distribution while continuing to monitor treated patients. Tazverik, originally developed by Epizyme, had accelerated and later full approvals in limited indications. Ipsen and analysts characterized the commercial impact as limited, but the move raises broader questions about confirmatory-trial surveillance and post-approval safety management for oncology agents.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.